CRYOPORT, INC. Payments to Develop Software
CRYOPORT, INC. (CYRX) reported Payments to Develop Software of $381.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToDevelopSoftware · last filed 2026-08-06
- CRYOPORT, INC. payments to develop software for the quarter ending 2025-12-31 was -$817.00K, a 753.60% decline year-over-year.
- CRYOPORT, INC. payments to develop software for the quarter ending 2025-09-30 was $587.00K, a 14.56% decline year-over-year.
- CRYOPORT, INC. payments to develop software for the quarter ending 2025-06-30 was $1.51M, a 7.60% decline year-over-year.
- CRYOPORT, INC. payments to develop software for the quarter ending 2025-03-31 was $555.00K, a 25.28% increase year-over-year.
- CRYOPORT, INC. payments to develop software for fiscal 2025 was $1.83M, a 36.52% decline from fiscal 2024.
- CRYOPORT, INC. payments to develop software for fiscal 2024 was $2.89M, a 44.97% decline from fiscal 2023.
- CRYOPORT, INC. payments to develop software for fiscal 2023 was $5.24M, a 255.28% increase from fiscal 2022.
- CRYOPORT, INC. payments to develop software for fiscal 2022 was $1.48M, a 69.66% increase from fiscal 2021.
| Period end | Payments to Develop Software 3 month | Payments to Develop Software 6 month | Payments to Develop Software 9 month | Payments to Develop Software 12 month |
|---|---|---|---|---|
| 2026-06-30 | $381.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | -$817.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$230.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $1.83M 10-K · filed 2026-03-05 |
| 2025-09-30 | $587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.09M derived: sum of 2 quarters · filed 2026-08-06 | $2.65M 10-Q · filed 2025-11-06 | $2.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.06M 10-Q · filed 2026-08-06 | $2.19M derived: sum of 3 quarters · filed 2026-08-06 | $2.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $555.00K 10-Q · filed 2026-05-05 | $680.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.37M derived: sum of 3 quarters · filed 2026-05-05 | $3.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $812.00K derived: sum of 2 quarters · filed 2026-03-05 | $2.44M derived: sum of 3 quarters · filed 2026-03-05 | $2.89M 10-K · filed 2026-03-05 |
| 2024-09-30 | $687.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2025-11-06 | $2.76M 10-Q · filed 2025-11-06 | $3.17M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.07M 10-Q · filed 2025-08-12 | $2.49M derived: sum of 3 quarters · filed 2026-03-05 | $4.78M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $443.00K 10-Q · filed 2025-05-08 | $857.00K derived: sum of 2 quarters · filed 2026-03-05 | $3.15M derived: sum of 3 quarters · filed 2026-03-05 | $5.22M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.71M derived: sum of 2 quarters · filed 2026-03-05 | $4.78M derived: sum of 3 quarters · filed 2026-03-05 | $5.24M 10-K · filed 2026-03-05 |
| 2023-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.37M derived: sum of 2 quarters · filed 2024-11-07 | $4.83M 10-Q · filed 2024-11-07 | $5.34M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.53M 10-Q · filed 2024-08-08 | $3.04M derived: sum of 3 quarters · filed 2025-03-07 | $3.45M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $463.00K 10-Q · filed 2024-05-08 | $974.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.38M derived: sum of 3 quarters · filed 2025-03-07 | $1.73M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $912.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.26M derived: sum of 3 quarters · filed 2025-03-07 | $1.48M 10-K · filed 2025-03-07 |
| 2022-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $752.00K derived: sum of 2 quarters · filed 2023-11-09 | $965.00K 10-Q · filed 2023-11-09 | $1.08M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $351.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $564.00K 10-Q · filed 2023-08-09 | $677.00K derived: sum of 3 quarters · filed 2024-03-13 | $985.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $213.00K 10-Q · filed 2023-05-04 | $326.00K derived: sum of 2 quarters · filed 2024-03-13 | $634.00K derived: sum of 3 quarters · filed 2024-03-13 | $890.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $421.00K derived: sum of 2 quarters · filed 2024-03-13 | $677.00K derived: sum of 3 quarters · filed 2024-03-13 | $870.00K 10-K · filed 2024-03-13 |
| 2021-09-30 | $308.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $564.00K derived: sum of 2 quarters · filed 2022-11-04 | $757.00K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $449.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $193.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $551.00K 10-K · filed 2023-02-28 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |